Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 10 2020
Historique:
pubmed: 28 5 2020
medline: 13 2 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

Cannabis use is consistently linked to poorer mental health outcomes, and there is evidence that use of higher-potency cannabis increases these risks. To date, no studies have described the association between cannabis potency and concurrent mental health in a general population sample or addressed confounding using longitudinal data. To explore the association between cannabis potency and substance use and mental health outcomes, accounting for preceding mental health and frequency of cannabis use. This cohort study used data from the Avon Longitudinal Study of Parents and Children, a UK birth cohort of participants born between April 1, 1991, and December 31, 1992. Present data on outcomes and exposures were collected between June 2015 and October 2017 from 1087 participants at 24 years of age who reported recent cannabis use. Self-reported type of cannabis most commonly used in the past year, coded to a binary exposure of use of high-potency cannabis or lower-potency cannabis. Outcomes were reported frequency of cannabis use, reported cannabis use problems, recent use of other illicit drugs, tobacco dependence, alcohol use disorder, depression, generalized anxiety disorder, and psychotic-like experiences. The study used secondary data; consequently, the hypotheses were formulated after data collection. Past-year cannabis use was reported by 1087 participants (580 women; mean [SD] age at onset of cannabis use, 16.7 [3.0] years). Of these, 141 participants (13.0%) reported the use of high-potency cannabis. Use of high-potency cannabis was associated with increased frequency of cannabis use (adjusted odds ratio [AOR], 4.38; 95% CI, 2.89-6.63), cannabis problems (AOR, 4.08; 95% CI, 1.41-11.81), and increased likelihood of anxiety disorder (AOR, 1.92; 95% CI, 1.11-3.32). Adjustment for frequency of cannabis use attenuated the association with psychotic experiences (AOR 1.29; 95% CI, 0.67-2.50), tobacco dependence (AOR, 1.42; 95% CI, 0.89-2.27), and other illicit drug use (AOR, 1.29; 95% CI, 0.77-2.17). There was no evidence of association between the use of high-potency cannabis and alcohol use disorder or depression. To our knowledge, this study provides the first general population evidence suggesting that the use of high-potency cannabis is associated with mental health and addiction. Limiting the availability of high-potency cannabis may be associated with a reduction in the number of individuals who develop cannabis use disorders, the prevention of cannabis use from escalating to a regular behavior, and a reduction in the risk of mental health disorders.

Identifiants

pubmed: 32459328
pii: 2765973
doi: 10.1001/jamapsychiatry.2020.1035
pmc: PMC7254445
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1044-1051

Subventions

Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209158/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/KO232331/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006727/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L022206/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/7
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17210
Pays : United Kingdom

Références

Psychol Med. 2018 Dec;48(16):2786-2793
pubmed: 29530110
Am J Psychiatry. 2020 Apr 1;177(4):308-317
pubmed: 31906710
Addiction. 2014 Oct;109(10):1686-94
pubmed: 24894801
Lancet. 2007 Jul 28;370(9584):319-28
pubmed: 17662880
Addiction. 2019 Jun;114(6):1015-1023
pubmed: 30597667
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Lancet Psychiatry. 2016 Sep;3(9):900-6
pubmed: 27374072
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Psychol Med. 1992 May;22(2):465-86
pubmed: 1615114
JAMA Psychiatry. 2019 Apr 1;76(4):426-434
pubmed: 30758486
Curr Drug Abuse Rev. 2012 Mar;5(1):32-40
pubmed: 22150622
Neuropsychopharmacology. 2004 Aug;29(8):1558-72
pubmed: 15173844
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Drug Test Anal. 2018 Apr;10(4):628-635
pubmed: 29441730
Psychol Med. 2015 Nov;45(15):3181-9
pubmed: 26213314
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Schizophr Res. 2008 Sep;104(1-3):279-86
pubmed: 18562177
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
Lancet Psychiatry. 2015 May;2(5):380
pubmed: 26360272
Drug Alcohol Depend. 2017 Sep 1;178:32-38
pubmed: 28624604

Auteurs

Lindsey A Hines (LA)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Tom P Freeman (TP)

Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, United Kingdom.
Institute of Psychiatry, Psychology & Neuroscience, National Addiction Centre, London, United Kingdom.
Clinical Psychopharmacology Unit, University College London, London, United Kingdom.

Suzanne H Gage (SH)

Addiction Group, Department of Psychological Sciences, University of Liverpool, Liverpool, United Kingdom.

Stanley Zammit (S)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom.

Matthew Hickman (M)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Mary Cannon (M)

Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland.

Marcus Munafo (M)

Experimental Psychology, University of Bristol School of Psychological Science, Bristol, United Kingdom.

John MacLeod (J)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Jon Heron (J)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH